Aller au contenu principal
Accès ouvert déclaré 2026 article

Increased ADORA1 expression in pancreatic islets coincides with insulin secretory defects in human type 2 diabetes

0Citations signalées — pas une note de qualité
6Institutions déclarées
3Pays d’affiliation déclarés

Résumé fourni par la source

Adenosine receptors (ADORAs) are G-protein coupled receptors that critically modulate cell function, yet their specific roles in regulating insulin and glucagon secretion remain incompletely understood. While RNA sequencing of isolated human islets, confirmed by qPCR, revealed that only ADORA1 and ADORA2A transcripts are abundantly expressed, mouse islets express all four receptor subtypes (Adora1, Adora2a, Adora2b, Adora3). Confocal immunofluorescence demonstrated ADORA1 protein localization in both islet β- and α-cells. Transcriptome correlation analysis of human islets identified 87 genes strongly associated with ADORA1 expression, enriched in pathways regulating carbohydrate and lipid metabolism, cell cycle, apoptosis, proliferation, endocrine system development, and metabolic disease. ADORA1 mRNA levels were positively correlated with HbA1c and elevated in islets of type 2 diabetes (T2D) donors, implicating ADORA1 in β-cell dysfunction. In ob/ob mouse islets, reduced Adora1 expression coincided with enhanced pulsatile insulin secretion, while the control islets showed a biphasic with a weaker second phase insulin secretory response. Adenosine efficiently suppressed insulin secretion in both ob/ob and control islets. ADORA1 antagonist DPCPX attenuated adenosine-induced suppression of insulin release. Adora1-KD mice exhibited a restored, pulsatile second-phase insulin response absent in controls. In human islets, adenosine suppressed both glucose-stimulated insulin secretion and cAMP generation, effects prevented by DPCPX. Adenosine also impaired β-cell viability and proliferation, which were rescued by ADORA1 inhibition. Collectively, our findings identify ADORA1 as a key inhibitory modulator of β-cell function under diabetogenic stress, thereby a promising therapeutic target to preserve insulin secretory capacity in early T2D.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Increased ADORA1 expression in pancreatic islets coincides with insulin secretory defects in human type 2 diabetes
Date Crossref
01/08/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Pancreatic function and diabetesDiabetes Treatment and ManagementDiabetes Management and Research

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.